Latest News
Cure SMA Advocacy Highlights of 2025
Thank you to the individuals with spinal muscular atrophy (SMA), their family members, and other supporters who helped advocate for SMA community priorities in 2025. As the year comes to […]
Read More ›Together, We’re Changing the Story of SMA
Watch the video and see how far we’ve come and the future we’re building together. Donate to Support the SMA Community Your support accelerates research, strengthens advocacy, and expands critical […]
Read More ›Cure SMA Shares Updates on the Phase 10 SMA Industry Collaboration
Earlier this year, Cure SMA launched an expanded Phase 10 of the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, SMA Europe, Cure […]
Read More ›Double Your Impact this Giving Tuesday!
Today is Giving Tuesday, and there’s an incredible opportunity to double your impact! The Luke 18:1 Foundation has stepped forward with a $50,000 gift and invited our community to double the […]
Read More ›Novartis Receives FDA Approval of Itvisma for the Treatment of SMA
Novartis today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Itvisma (onasemnogene abeparvovec-brve) to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). Itvisma […]
Read More ›Scholar Rock and Cure SMA Share Update on Apitegromab and FDA Meeting
Read the Scholar Rock community statement here. Scholar Rock recently held an in-person Type A meeting with the FDA on November 12 to discuss the Biologics License Application (BLA) […]
Read More ›